B2BMedium Effortglobal

LeanGuard — White-Label GLP-1 Adherence & Lean-Mass Protection Layer for Weight-Loss Clinics

The first GLP-1 wave was about access. The next wave is about not failing after access.

Score79/100
Apr 9, 2026
TAM
€9.9B — 55M projected US GLP-1 users by 2035 × roughly €15/month equivalent digital-support spend; excludes clinic upsells and non-US markets.
SAM
€540M — 5M active users served by obesity clinics / telehealth programs in US, Canada, UK, and EU with a realistic €9/month support layer.
SOM
€1.2M — 20 clinic customers × 500 active patients × €10 PMPM in years 1-2.
WhatsAppB2BB2CHealth

The Problem

The first GLP-1 wave was about access. The next wave is about not failing after access.

The current market is full of prescription-first programs that stop short of the hard part: helping patients stay adherent, protect lean mass, handle nausea/constipation, eat enough protein, keep resistance training consistent, and avoid disengaging when progress slows.

The evidence is getting clearer:

  • Reuters / KFF: roughly 1 in 8 US adults have taken a GLP-1, and 54% of prior users said affordability was challenging even with insurance.
  • Morgan Stanley (Apr 2026) raised its 2035 US usage projection to 55M users, implying this is not a niche clinic workflow anymore.
  • Frontiers mini-review (2025) argues the winning model is hybrid care: GLP-1s + exercise + protein + long-term behavior support, because medication alone often leads to weight regain after discontinuation and poorer lean-mass outcomes.
  • Cloudcure (Mar 2026) explicitly launched a companion app to close the “clinical adherence gap,” validating that the missing product layer is not more prescribing but better follow-through.

Ready to build this?

This idea scored 79/100. Get tomorrow's in your inbox, free, no account needed.

Free forever. One idea per day. Unsubscribe anytime.